Charles Schwab Investment Management Inc Amylyx Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 302,270 shares of AMLX stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
302,270
Previous 521,619
42.05%
Holding current value
$1.59 Million
Previous $991,000
1.21%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding AMLX
# of Institutions
127Shares Held
44.4MCall Options Held
235KPut Options Held
530K-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$24.5 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$16.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$14.1 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$11.2 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$10.7 Million0.04% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $308M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...